Side Effects of boceprevir: A Synthesis of Findings from 29 Studies

  1. Home
  2. Side Effects of boceprevir
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of boceprevir: A Synthesis of Findings from 29 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of boceprevir: A Synthesis of Findings from 29 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Boceprevir is a type of direct-acting antiviral drug used to treat chronic hepatitis C. Boceprevir has shown significantly higher SVR (sustained virological response) rates in clinical trials, particularly in patients with unfavorable prognostic factors, when used in combination therapy with peginterferon α and ribavirin. 27

Boceprevir has an inhibitory effect on NS3/4A protease of the hepatitis C virus (HCV) and has an effect of suppressing the growth of HCV. 6

Boceprevir is expected to enhance the treatment effect of HCV in combination therapy with peginterferon α and ribavirin. 20

Research results suggest that boceprevir may enhance the efficacy of the standard treatment, combination therapy with peginterferon α and ribavirin, in patients with HCV genotype 1 infection. 7

Boceprevir is gaining attention as a treatment option for patients with HCV genotype 1 infection. 16

Reasons for Side Effects

While boceprevir has an effect of suppressing the growth of HCV, it may cause some side effects. 5

Boceprevir may have a higher incidence of side effects in combination therapy with peginterferon α and ribavirin. 22

Common Side Effects

Rash

Boceprevir may cause rash. 27 9

Anemia

Boceprevir may cause anemia. 27 29

Drug Rash with Eosinophilia and Systemic Symptoms (DRESS)

Boceprevir may cause drug rash with eosinophilia and systemic symptoms (DRESS). 9

Kidney Dysfunction

Boceprevir may cause kidney dysfunction. 4

Countermeasures for Side Effects

Rash

If you experience a rash, consult your doctor. 27

Anemia

If you experience anemia, consult your doctor. Anemia medications may be prescribed if necessary. 27

Drug Rash with Eosinophilia and Systemic Symptoms (DRESS)

If you experience drug rash with eosinophilia and systemic symptoms (DRESS), consult your doctor immediately. DRESS is a serious side effect and early treatment is important. 9

Kidney Dysfunction

If you experience kidney dysfunction, consult your doctor. Kidney dysfunction medications may be prescribed if necessary. 4

Comparison Between Studies

Commonalities in Studies

Multiple studies have suggested that boceprevir may enhance the efficacy of treatment for patients with HCV genotype 1 infection. 27 6 20 7 16

Also, multiple studies have shown that boceprevir may cause some side effects. 5 22

Differences in Studies

Research results on the side effects of boceprevir may vary depending on the study. 27 6 20 7 16 5 22

For example, one study reported rash as the most common side effect, while another study reported anemia as the most common side effect. 27

Precautions for Applying to Real Life

Boceprevir is gaining attention as a treatment option for patients with HCV genotype 1 infection. 16

However, boceprevir may cause some side effects. 5

When using boceprevir, be sure to discuss the risks and benefits of side effects with your doctor. 5

Limitations of Current Research

There is still not enough research on boceprevir. 5

In particular, the long-term side effects of boceprevir are not yet fully understood. 5

Directions for Future Research Needed

Further research is needed on the long-term side effects of boceprevir and its effectiveness in combination with other treatments. 5

It is also important to research the differences between patients who respond well to boceprevir and those who do not. 5

Conclusion

Boceprevir is gaining attention as a treatment option for patients with HCV genotype 1 infection. 16

However, boceprevir may cause some side effects. 5

When using boceprevir, be sure to discuss the risks and benefits of side effects with your doctor. 5

Keywords
Benefit Keywords
Hepatitis C treatment
1
HCV treatment
2
HCV treatment
3
HCV treatment
4
Hepatitis C treatment
5
HCV treatment
Improved efficacy
6
HCV treatment
Improved efficacy
Personalized therapy
7
HCV treatment
IFN-free therapy
8
Hepatitis C treatment
9
Improved safety and tolerability
Increased sustained virological response
10
Hepatitis treatment
12
Hepatitis treatment
13
DAA treatment
HCV diagnosis
14
Improved HCV treatment
Sustained virologic response
15
Hepatitis C cure
Treatment duration shortened
16
HCV GT1 treatment
17
Drug development
HCV treatment
18
HCV infection
19
Hepatitis C virus treatment
Sustained virological response
20
Triple therapy for HCV genotype 1 and HIV
21
Fewer side effects
HCV treatment
High SVR rates
Lower pill burdens
22
HCV RNA reduction
23
Hepatitis C eradication
IFN-free regimens
24
C4 increase
Cryoglobulin reduction
HCV-MC treatment
25
Hepatitis C virus treatment
26
Higher SVR rates
27
Early HCV response
28
Antimitogenic effects
Antiviral effects
Immunostimulatory effects
29
Risk Keywords
Toxicity
1
MELD score increase
Renal impairment
4
Adverse events
5
Side effects
6
Iron overload
Side effects
7
Side effects
8
Drug rash
Eosinophilia
Systemic symptoms
9
Complicated treatment algorithms
Drug interactions
Side effects
10
Seizures
11
Drug resistance
Side effects
12
Drug resistance
13
Treatment complexity
14
Anemia
Rectal irritation
15
Multiple side effects
16
Side effects
18
Resistance
Viral breakthrough
19
Drug resistance
20
Cytopenias
Death
23
Drug-drug interactions
Side effects
24
Anaemia
Neutropenia
Thrombocytopenia
25
Anemia
Rash
27
Anemia
Early discontinuation
Futility
Neutropenia
Thrombocytopenia
28
Autoimmune Phenomena
Myasthenia gravis
29
Literature analysis of 29 papers
Positive Content
26
Neutral Content
2
Negative Content
1
Article Type
1
0
0
17
29
1.

Emerging therapeutic options for the management of hepatitis C infection.

Author: ThompsonJ Richard

Hepatitis C treatment
Toxicity

This paper reviews agents in late-phase development for the future treatment of hepatitis C. These agents offer improved sustained virological response (SVR) rates compared to traditional therapies, and some are being developed for oral administration once daily.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

2.

Medicinal plants against hepatitis C virus.

Author: AshfaqUsman A, IdreesSobia

HCV treatment

This review summarizes medicinal plants and their phytochemicals that inhibit different stages of the hepatitis C virus (HCV) life cycle. These natural compounds have potential for use in HCV therapy, especially as current treatment options have limitations in effectiveness and side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

3.

[New direct-acting antiviral agents for the treatment of chronic hepatitis C in 2014].

Author: CornbergM, Höner zu SiederdissenC, MaasoumyB, MannsM P

HCV treatment

Direct-acting antiviral agents (DAA) have shown significant progress in treating hepatitis C virus (HCV) infection. While earlier DAA, such as boceprevir and telaprevir, required combination therapy with pegylated interferon α and ribavirin, newer DAA, such as sofosbuvir and simeprevir, offer simplified treatment options.

English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : German

6.

Antiviral treatment of hepatitis C virus infection and factors affecting efficacy.

Author: ZhuYan, ChenSong

HCV treatment
Improved efficacy
Side effects

HCV infection is a major cause of liver disease. The standard of care (SOC) is polyethylene glycol interferon-α (PegIFN-α) with ribavirin (RBV), but efficacy is low for genotype 1. New direct-acting antiviral (DAA) drugs offer higher specificity, efficacy, and fewer side effects, potentially becoming optimal regimens in the future.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

9.

First case of drug rash eosinophilia and systemic symptoms due to boceprevir.

Author: SamainAgnès, Duval-ModesteAnne-Bénédicte, JolyPascal, LeblancCéline, MassyNathalie, CourvillePhilippe, GoriaOdile, RiachiGhassan

Hepatitis C treatment
Drug rash
Eosinophilia
Systemic symptoms

This case report describes a patient who developed drug rash with eosinophilia and systemic symptoms (DRESS) due to boceprevir, an antiviral drug used to treat hepatitis C.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

10.

Advances in the management of hepatitis C.

Author: CroaghC M, LubelJ

Improved safety and tolerability
Increased sustained virological response
Complicated treatment algorithms
Drug interactions
Side effects

This article reviews recent advancements in hepatitis C virus (HCV) treatment, including the use of new antiviral agents like boceprevir and telaprevir. While these new regimens offer improved cure rates, they also present challenges with complex treatment algorithms, drug interactions, and potential side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

11.

Seizures in patients with chronic hepatitis C treated with NS3/4A protease inhibitors: does pharmacological interaction play a role?

Author: MilazzoLaura, FalvellaFelicia Stefania, MagniCarlo, GervasoniCristina, PeriAnna Maria, CattaneoDario, AntinoriSpinello, VidaleSimone

Seizures

This report describes two cases of new onset seizures occurring in patients receiving anti-HCV therapy with Peg-IFN, ribavirin, and HCV protease inhibitors.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

12.

Optimizing DAA management in daily practice.

Author: SerfatyLawrence

Hepatitis treatment
Drug resistance
Side effects

Triple therapy with telaprevir or boceprevir for genotype 1 hepatitis C virus infection has shown significant benefits but also presents new challenges. This article outlines a checklist approach for managing triple therapy, including pre-treatment considerations, adherence strategies, potential side effects, and management of treatment failure.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

13.

Resistance to HCV nucleoside analogue inhibitors of hepatitis C virus RNA-dependent RNA polymerase.

Author: NajeraIsabel

Hepatitis treatment
Drug resistance

New compounds are needed to achieve higher cure rates and reduce side-effects in the treatment of hepatitis C virus (HCV) genotype 1 infection. This review discusses the potential of nucleos(t)ide analogues for combination therapy, considering their high barrier to resistance and pangenotypic activity.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

16.

Treatment of hepatitis C monoinfection in adults--Dutch national guidelines.

Author: LamersM H, BroekmanM M T J, BoucherC A, BrouwerJ T, BurgerD M, van HoekB, HoepelmanA I M, de KnegtR J, ReesinkH W, DrenthJ P H,

Hepatitis C cure
Treatment duration shortened
Multiple side effects

First-generation direct antiviral agents, boceprevir and telaprevir, have revolutionized the treatment of chronic hepatitis C genotype 1 infection in adults. While improving cure rates and treatment duration, they are associated with significant side effects that need to be carefully managed.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Practice GuidelineGuidelines and recommendations for the diagnosis and treatment of specific medical conditions in medical practice.

Language : English

17.

[HCV reinfection after liver transplantation - management and first experiences with telaprevir-based triple therapy].

Author: HerzerK, Papadopoulos-KöhnA, TimmJ, PaulA, JochumC, GerkenG

HCV GT1 treatment

This study reports the first experiences with telaprevir-based triple therapy in patients with hepatitis C virus (HCV) genotype 1 reinfection of the liver graft after transplantation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : German

18.

HCV-targeted antivirals: current status and future challenges.

Author: GemmaSandra, BrogiSimone, NovellinoEttore, CampianiGiuseppe, MagaGiovanni, BrindisiMargherita, ButiniStefania

Drug development
HCV treatment
Side effects

This review discusses the development of small-molecule inhibitors targeting the hepatitis C virus (HCV) enzymes NS3/4A protease, NS5B and NS5A, with a focus on the latest advances in rational drug design for NS3 protease inhibitors.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

19.

Current and future therapies for hepatitis C virus infection: from viral proteins to host targets.

Author: ImranMuhammad, ManzoorSobia, KhattakNasir Mahmood, KhalidMadiha, AhmedQazi Laeeque, ParvaizFahed, TariqMuqddas, AshrafJaved, AshrafWaseem, AzamSikandar, AshrafMuhammad

HCV infection
Resistance
Viral breakthrough

This review explores current and future therapies for hepatitis C virus (HCV) infection. The current standard-of-care treatment involves Peg-interferon, ribavirin, and protease inhibitors. Future therapies are likely to focus on combinations of direct-acting agents without the use of interferon.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

20.

Direct-acting antivirals for the treatment of chronic hepatitis C: open issues and future perspectives.

Author: ChaeHee Bok, ParkSeon Mee, YounSei Jin

Hepatitis C virus treatment
Sustained virological response
Drug resistance

This review discussed the current and future landscape of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection, highlighting the challenges of viral resistance and the promising potential of oral drug combinations for achieving sustained virological response (SVR).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

21.

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

Author: SulkowskiMark, PolStanislas, MallolasJosep, FainboimHugo, CooperCurtis, SlimJihad, RiveroAntonio, MakCarmen, ThompsonSeth, HoweAnita Y M, WenningLarissa, SklarPeter, WahlJanice, GreavesWayne,

Triple therapy for HCV genotype 1 and HIV

This study aimed to assess the efficacy and safety of triple therapy with boceprevir, peginterferon alfa-2b, and ribavirin in patients with hepatitis C virus (HCV) genotype 1 and HIV.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

22.

Review of direct-acting antiviral agents for the treatment of chronic hepatitis C.

Author: ShahNihar, PierceTracey, KowdleyKris V

Fewer side effects
HCV treatment
High SVR rates
Lower pill burdens

This review discusses the rapid advancements in the treatment of hepatitis C virus (HCV) infection, specifically the development of direct-acting antivirals (DAAs). The review highlights the advantages of DAA regimens, including high cure rates and fewer side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

23.

Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation.

Author: PungpapongSurakit, AqelBashar A, KoningLudi, MurphyJennifer L, HenryTanisha M, RylandKristen L, YatacoMaria L, SatyanarayanaRaj, RosserBarry G, VargasHugo E, CharltonMichael R, KeavenyAndrew P

HCV RNA reduction
Cytopenias
Death

Telaprevir and boceprevir combined with peginterferon and ribavirin achieved on-treatment virological response rates of approximately 50% to 60% in patients with recurrent HCV after LT. Significant side effects were common.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

24.

Pretransplant and posttransplant treatment of hepatitis C virus infection with protease inhibitors.

Author: LondoñoMaria-Carlota, CrespoGonzalo, FornsXavier

Hepatitis C eradication
IFN-free regimens
Drug-drug interactions
Side effects

Antiviral therapy with protease inhibitors substantially increases the number of patients achieving sustained hepatitis C virus eradication, either before or after liver transplantation. However, side effects and drug-drug interactions are considerable, and careful selection and management of patients will be crucial.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

25.

Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24.

Author: SaadounDavid, Resche RigonM, ThibaultV, LonguetM, PolS, BlancF, PialouxG, KarrasA, Bazin-KarraD, CazorlaC, VittecoqD, MussetL, DecauxO, ZizaJ M, LambotteO, CacoubPatrice

C4 increase
Cryoglobulin reduction
HCV-MC treatment
Anaemia
Neutropenia
Thrombocytopenia

Pegylated interferon α/ribavirin/protease inhibitor combination was highly effective in patients with hepatitis C virus-mixed cryoglobulinemia vasculitis. This combination should be administered cautiously considering the high rate of side effects.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

26.

A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.

Author: ChenEmerson Y, SclairSeth N, CzulFrank, ApicaBetty, DubinPerry, MartinPaul, LeeWilliam M

Hepatitis C virus treatment

Protease inhibitor triple therapy has been shown to be effective in treating hepatitis C virus (HCV) infection. This study investigated the use of this therapy in the United States following FDA approval.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

29.

Pegylated interferon induced myasthenia crisis--a case report.

Author: CongeniJonathan P, KirkpatrickRobert B

Antimitogenic effects
Antiviral effects
Immunostimulatory effects
Autoimmune Phenomena
Myasthenia gravis

We present a case of interferon-induced myasthenia crisis that developed soon after retreatment of hepatitis C with combination interferon, ribavirin, and telaprevir.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.